Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
Active, not recruiting · NCT06369467 · Registry updated 2026-06-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy | EAST syndrome, Hypersensitivity, Immediate, food allergy, immune system disorder | Active, not recruiting | Phase 1 | 2026-06-26 | NCT06369467 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Regeneron Pharmaceuticals | 238 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University - Winship Cancer Institute | Atlanta | United States | 11 |
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| The Children's Hospital of Philadelphia | Philadelphia | United States | 62 |
| University of South Florida | Tampa | United States | 23 |